The therapeutic landscape for RCC continues to evolve, driven by the introduction of new first line treatment combinations with TKIs and IOs. Despite recent advancements, Real-world evidence (RWE) on patient characteristics, clinical outcomes, and treatment patterns remain limited. This study aims to leverage secondary data to generate real-world insights, with the goal of informing valuable clinical strategies and improving patient outcomes.
